
\begin{table}[htb]\centering
\caption{Logit Marginal Effects\\Dependent variable: Generous PPM}
\begin{tabular}{l*{8}c}

 & (1) & (2) & (3) & (4) & (5) & (6) & (7) & (8)  \\
 & All & All & All & All (clustered SE) & Recent & Recent & Recent & Recent (clustered SE)  \\

                    &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   \\

\hline

       &               &               &               &               &               &               &               &               \\
Trial start year    &      0.0023***&      0.0023***&      0.0023***&      0.0025***&      0.0035***&      0.0035***&      0.0035***&      0.0038***\\
                    &    (0.0001)   &    (0.0001)   &    (0.0001)   &    (0.0002)   &    (0.0002)   &    (0.0002)   &    (0.0002)   &    (0.0002)   \\
\shortstack[l]{Phase 2 Clinical\\(includes Phase 2/Phase 3 trials)}&      0.0129***&               &      0.0126***&      0.0137***&      0.0150***&               &      0.0146***&      0.0159***\\
                    &    (0.0013)   &               &    (0.0013)   &    (0.0021)   &    (0.0014)   &               &    (0.0014)   &    (0.0021)   \\
Phase 3 Clinical    &      0.0216***&      0.0215***&      0.0211***&      0.0230***&      0.0234***&      0.0233***&      0.0228***&      0.0248***\\
                    &    (0.0018)   &    (0.0018)   &    (0.0018)   &    (0.0040)   &    (0.0020)   &    (0.0020)   &    (0.0020)   &    (0.0042)   \\
Trial site in US=1  &      0.0028*  &      0.0027*  &      0.0027*  &      0.0028** &      0.0028*  &      0.0026*  &      0.0028*  &      0.0028*  \\
                    &    (0.0012)   &    (0.0012)   &    (0.0012)   &    (0.0009)   &    (0.0013)   &    (0.0013)   &    (0.0013)   &    (0.0011)   \\
Drug indication for neoplasm&      0.1153***&      0.1150*** &      0.1167***&      0.1202***&      0.1207***&      0.1203***&      0.1252***&      0.1288*** \\
                    &    (0.0013)   &    (0.0013)   &    (0.0013)   &    (0.0016)   &                  (0.0013)   &    (0.0013)   &    (0.0014)   &    (0.0018)  \\
Received NIH funding&     -0.0062** &     -0.0062** &     -0.0051*  &     -0.0051***&     -0.0068*  &     -0.0069*  &     -0.0055*  &     -0.0056***\\
                    &    (0.0024)   &    (0.0024)   &    (0.0024)   &    (0.0007)   &    (0.0027)   &    (0.0027)   &    (0.0027)   &    (0.0007)   \\
Biomarker type: genomic&      0.1734***&      0.1733***&      0.1736***&      0.1825***&      0.1794***&      0.1794***&      0.1797***&      0.1889***\\
                    &    (0.0025)   &    (0.0025)   &    (0.0025)   &    (0.0076)   &    (0.0028)   &    (0.0028)   &    (0.0028)   &    (0.0086)   \\
Phase 2 only        &               &      0.0132***&               &               &               &      0.0153***&               &               \\
                    &               &    (0.0013)   &               &               &               &    (0.0014)   &               &               \\
Phase 2/3 Clinical  &               &      0.0055   &               &               &               &      0.0062   &               &               \\
                    &               &    (0.0043)   &               &               &               &    (0.0047)   &               &               \\
N                   &      113410   &      113410   &      113410   &      106626   &       96254   &       96254   &       96254   &       90650   \\
* p$<$0.05, ** p$<$0.01, *** p$<$0.001 \\

\end{tabular}
\end{table}

